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Background: Despite the modern therapies available for treating glioblastoma multiforme (GBM), it is still a deadly
disease. The development of new therapeutic strategies for the management of gliomas is therefore crucial. The
present study is designed to analyze the therapeutic potentials of synthetic compound N-(2-hydroxyphenyl)acetamide
(NA-2) in the treatment of GBM as a single agent or in combination with Temozolomide (TMZ) on glioblastoma cells.
Methods: MTT and TUNEL assays were used to detect the growth inhibitory effect and apoptotic activity of NA-2 alone
and in combination with TMZ. Synergy was assessed using combination Index method. The expression of apoptosis
related markers Bax, Bcl-2 and caspase-3 were assessed by RT-PCR, whereas, the active caspase-3 protein expression
was determined using imunocytochemistry.
Results: Both NA-2 and TMZ inhibited the growth of U87 in a dose dependent manner. The combine administration
of NA-2 (0.33 mM) and temozolomide (0.1 mM) significantly enhanced the cell growth inhibition and apoptosis.
Furthermore RT-PCR and imunocytochemistry data revealed that cooperative apoptosis induction was associated with
increased ratio of Bax to Bcl-2 and active Caspase-3 expression.
Conclusion: Our findings support that NA-2 possesses strong apoptotic activity and the combined administration of
NA-2 and TMZ may be therapeutically exploited for the management of GBM.
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Glioblastoma multiforme (GBM) is a malignant, invasive
and most commonly occurring tumor of the central ner-
vous system [1,2]. It accounts for approximately 60% of all
malignant primary brain tumors in adults [2]. According
to WHO classification of tumors, GBM has been desig-
nated as grade IV tumor [3]. GBM has shown poor
response to even very aggressive treatment and patients
usually have a median survival of approximately 12 to
15 months after diagnosis [4,5]. Current options available
for the treatment of GBM (gross total resection along with* Correspondence: shabana.simjee@iccs.edu
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unless otherwise stated.radio and chemotherapy) are only soothing [4,5]. Al-
though chemotherapeutic agent temozolomide (TMZ)
(an oral alkylating agent) has shown some efficacy in
delaying the progression of the disease and quality of life,
long-lasting responses have not been reported and ultim-
ately patients die of the disease [6]. There are diverse
mechanisms of action through which TMZ exerts its anti-
tumor effect. TMZ is capable of significantly increasing
the sensitivity of O6 methyl guanine– DNA methyl trans-
ferase (MGMT)-negative GBMs to radiotherapy [7]. This
effect of TMZ is produced by its ability to increase the
extent of radiation induced double strand DNA damage
[7]. To some extent TMZ exerts its cytotoxic activity by
pro-autophagic [8] and/or apoptotic pathway [9].
In addition to alkylating agents the use of non-steroidal
anti-inflammatory drugs (NSAIDs) and Bevacizumab
(BVZ), a humanized monoclonal antibody has also beenhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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survival of patients with newly diagnosed GBM [13] and
also demonstrated several side effects including GIT perfor-
ation, wound dehiscence, leukoencephalopathy syndrome,
intracranial hemorrhage, kidney damage, and heart failure
[12,14]. As far as NSAIDs are concerned, although they can
alter cell cycle distribution, inhibit cyclins, modulate Bcl-2
family proteins and induce apoptosis [15], their prolong use
have been found to be associated with various side effects
[16]. Therefore there is a need of developing new com-
pounds which can be use as a single agent therapy or else
can be used in combination with low doses of conven-
tional drugs.
N-(2-hydroxyphenyl)acetamide (NA-2) also known as,
O-acetaminophenol and 2-acetylaminophenol, is a deriva-
tive of salicylic acid which has been reported by Saeed and
Saeed [17] as less toxic compound compared to paraceta-
mol or aspirin with an anti-platelet aggregating and anti-
inflammatory activity. Apart from this patent application
documents, to our knowledge not much work has been
done on this compound. This compound was also studied
in our laboratory in chronic inflammatory model of painTest Groups (NA-2 treatment) P  Value
0.165 mM and 0.33 mM < 0.001
0.33 mM and 0.66 mM > 0.05
0.66 mM and 1.32 mM < 0.001
1.32 mM and 2 mM < 0.01
(A)
Figure 1 Effect of NA-2 (A) and TMZ (B) on U87 cells growth inhibitio
for 24 hrs and MTT assay was performed. Both NA-2 and TMZ inhibited the
represents mean ± S.E.M of three independent experiments. Significant diff
***P <0.001.and it was also observed to show inhibitory affects on
inflammatory cytokines and ROS/RNS [18,19]. Therefore
in the present study we aimed to explore the activity of
NA-2 on growth inhibition of GBM cells when given as
a single agent or in combination with TMZ and to
examine whether apoptosis is involve in the cell growth
inhibition. In our preliminary study NA-2, has shown
promising results in apoptotic assay and also exhibited
anti-proliferative activity.Results
Growth Inhibitory effect of NA-2 and TMZ alone on
U87 GBM cells
Following the 24 hrs treatment of U87 GBM cells with
varying concentrations of NA-2 and TMZ, the growth in-
hibitory effect was evaluated using MTT assay. Both NA-2
and TMZ significantly inhibited the growth of U87 cells in
dose dependent manner (Figure 1 A & B). ANOVA with
bonferroni’s post hoc test was used to assess the level of
significance within the test doses and the data is repre-
sented in Figure 1.Test Groups (TMZ treatment) P  Value
0.025 mM and 0.05 mM < 0.01
0.05 mM and 0.1mM < 0.01
0.1 mM and 0.2mM > 0.05
0.2 mM and 0.4mM >0.05
0.4 mM and 0.5 mM <0.05
(B)
n. Cells were treated with different concentrations of NA-2 and TMZ
growth of U87 cells in concentration dependent manner. Each bar
erence between vehicle control and treated cells are indicated by
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was also checked on the pancreatic cancer cells (PSN-1
cell line) using the cell titer blue (CTB) assay. Fluores-
cence was measured on SpectraMax® spectrofluorimeter
at 544 nm as an excitation wavelength and 590 nm as an
emission wavelength. All measurements were performed
in triplicate. The PSN-1 cells were treated with various
concentrations of NA-2 (0.165, 0.33, 0.66, 1.32 mM) for
24 hr. A significant concentration-dependent inhibition
on the viability of PSN-1 cells was observed (data pro-
vided as a Additional file 1: Figure S1).
Synergistic activity of NA-2 and TMZ
In order to determine whether the growth inhibitory ac-
tivity of TMZ is enhanced by NA-2, we treated U87 cells
with various combinations of these drugs for 24 hrs andCombination Doses
TMZ 0.1mM + NA-2 0.33mM
Figure 2 Effect of NA-2 and TMZ alone and in combinations on U87 c
combinations for 24 hrs and MTT assay was performed. Significant increase
0.33 mM of NA-2. Each bar represents mean ± S.E.M of three independent
individual drug treated cells and the cells receiving combined treatment o
control and treatment groups is indicated by ***P <0.001. Row under the f
According to the absorbance of each group, AB is the ratio of the combina
groups to control group. Therefore, CDI value greater than, equal to or
synergistic respectively. The results show that TMZ and NA-2 synergistic
0.1 mM and 0.33 mM respectively.MTT assay was performed. Data was analyzed and it
was found that growth inhibition increased significantly
(P <0.001) when TMZ 0.1 mM combined with 0.33 mM
of NA-2, as compared to their individual treatment
(Figure 2). Coefficient of drug interaction (CDI) values
were also calculated to determine whether the combined
effect of TMZ and NA-2 was synergistic, additive or
antagonistic. The combine effect of TMZ 0.1 mM with
0.33 mM of NA-2 was found to be synergistic with a
CDI value of 0.89. Doses that produce synergistic effect
were used for further studies.
Combined pro-apoptotic effect of NA-2 and TMZ
U87 cells were treated with NA-2 (0.33 mM) and (TMZ
0.1 mM) alone and in combination for 24 hrs and apop-
tosis was detected by TUNEL assay. We found thatCDI Value
<1
ells growth inhibition. Cells were treated NA-2, TMZ and their
in growth inhibition was observed when TMZ (0.1 mM) combine with
experiments. One-way ANOVA reveals a significant difference between
f TMZ/NA-2 (###P <0.001). Whereas significant difference between
igure represents the coefficient of drug interaction (CDI) = AB/(A × B).
tion groups to control group; A or B is the ratio of the single agent
less than 1 specifies that the drugs are antagonistic, additive or
ally inhibit growth of U87 cells when given in combination of
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apoptosis than the individual treatment of the drug
(Figure 3A). Only 31.7% ±1.81% and 20.5% ±1.46% of
apoptosis was observed when cells were treated with
NA-2 and TMZ alone. Whereas, the percentage of apop-
totic cells was dramatically increased to 53.6% ±1.40% in
case of combination treatment (Figure 3B).
Effect of NA-2, TMZ and their combination treatment on
Bcl-2, Bax and Caspase-3 expression
A balance between the expression of pro-apoptotic
protein (Bax) and anti-apoptotic protein (Bcl-2) plays an
important role in the initiation of apoptosis. Caspase 3
being an ultimate executioner is very important for
apoptosis. We therefore studied the ratio of Bax to Bcl-2
and caspase-3 gene expressions at transcriptional level
in drug treated and control cells by RT-PCR and the
level of Bax, Bcl-2 and caspase-3 gene expression was
normalized to β-actin.
Our results clearly shows that treatment with NA-2
alone leads to significant decrease in Bcl-2 expression as
compare to control While no significant difference wasFigure 3 (A) Representative photomicrographs presenting increased
NA-2 revealed by TUNEL assay. U87 cells were treated with TMZ and NA
method was used to detect apoptotic cells and photographs were taken u
apoptosis and is strongest in cells treated with TMZ and NA-2 in combinat
assay and each bar represents mean ± S.E.M of three independent experim
indicated by **P <0.01 and ***P <0.001. Whereas the significant difference
treatment is indicated by $$$P <0.001, ###P <0.001 respectively.observed in case of TMZ treatment (Figure 4). More-
over, further decrease in Bcl-2 was observed in the
group receiving combination treatment of TMZ with
NA-2. On the contrary, combination treatment showed
more significant increase in Bax expression as compared
to the control and individual drug treatment and these
changes in Bcl-2 and Bax gene expression leads to
dramatic increase in Bax to Bcl-2 ratio in cells exposed
to combined treatment of TMZ and NA-2 than their
individual treatment. Likewise, profound increase in
caspase-3 expression was observed in cells treated with
TMZ and NA-2 in combination.
Effect of NA-2, TMZ and their combination treatment on
active Caspase-3 protein expression
To determine whether caspase-3 play a role in TMZ
and/or NA-2 mediated apoptosis of U87 cells, we
assessed activated caspase-3 protein level in both control
and drug treated groups (NA-2, TMZ and NA-2 + TMZ)
using imunocytochemistry. As shown in Figure 5 (A)
and (B) treatment of U87 cells with NA-2 and TMZ as
single agent leads to minor but significant increase inapoptosis in cells exposed to temozolomide in combination with
-2 as single agent or in combination as indicated. After 24 hrs TUNEL
nder the microscope. Note that the dark brown stain is indicative of
ion. (B) Bar graph showing percentage of apoptotic cells by TUNEL
ents. Significant difference between vehicle control and treated cells is











Figure 4 (See legend on next page.)
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Figure 4 Effect of NA-2, TMZ and their combination on Bcl-2, Bax and Caspase-3 expression. Representative bands for BCL-2, BAX and
Caspase-3 detected by RT PCR in vehicle control and treated cells. The housekeeping gene β-actin was amplified as an internal control. Graphic
illustration of Bcl-2, Bax, Bax/ Bcl-2 ratio and Caspase-3 gene after normalizing with their β-actin expression also shown. Combination treatment
with NA-2 and TMZ induce marked changes in the expression of all three mentioned genes as compared to their individual treatment. Each bar
represents mean ± S.E.M of three independent experiments. Significant difference between vehicle control and treated cells was indicated by
*P <0.05, **P <0.01, ***P <0.001. The significant difference between the individual drugs NA-2 and TMZ and their combination treatment is
indicated by $$P <0.01, $$$P <0.001 and ###P <0.001 respectively.
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trol. Moreover, marked elevated expression was observed
in the group receiving combination treatment of TMZ
with NA-2 as compare to control and their individual
treatment group.
Discussion
Although an alkylating agent TMZ has improved the
treatment of malignant gliomas, long-term therapeutic
responses are not observed and the majority of patients’
die due to aggressive progression of the disease [6]. It is
therefore interesting to search for ways to facilitate
therapeutic compound and their combination effect with
different drugs. In the present study, our results demon-
strate that NA-2 and TMZ inhibits the growth of U87
cells in dose dependent manner. The growth inhibitory
activity of NA-2 was found to be related to apoptosis. It
was also observed that NA-2 possesses synergistic ap-
optotic activity in combination with TMZ. Our results
are supported by the studies demonstrating in vitro
apoptosis-inducing ability of NSAIDs [20,21]. Non-
steroidal anti-inflammatory drugs such as acetylsalicylic
acid (aspirin) has been reported to induce apoptosis in
various cancer cell line and known to reduce the viability
of Glioblastoma cells to 46% when given at a concentra-
tion of 5 mM [22] which is approximately 3 fold higher
then the IC50 1.7 mM of NA-2. It induces apoptosis at a
dose of 8 mM [22] where as in case of NA-2 only
0.33 mM was sufficient to induce apoptosis in 37.1%
cells and increased to 53.6% when given in combination
with TMZ.
Apoptosis or programmed cell death is an important
physiological process that has a crucial role in development
and tissue homeostasis [23]. Nevertheless, it is also involved
in various pathological conditions. Its defects are common
occurrence in oncogenesis and contribute to drug resistance
[24]. It is also found to be deregulated in gliomas [25] and
therefore it is interesting to target underlying molecular
markers involved in the apoptotic process. Class of cysteine
protease called caspases and Bcl-2 family proteins [25] are
important group of proteins involved in apoptotic cell death
[26]. Pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) proteins
are subgroup of Bcl-2 family proteins that promotes and
inhibit apoptosis respectively [27]. Increased levels of Bcl-2
protein is observed in many tumor cells, contributes toincreased tumor cell resistance and tumor growth by
decreasing Bax-Bcl-2 ratio. Bax in itself does not cause cell
death, but its elevated expression favors an entry into the
apoptotic program following a death signal by countering
Bcl-2 activity. Thus, tilting the intracellular balance towards
an increased Bax-Bcl-2 ratio which can occur through either
elevated synthesis of Bax or through decreased synthesis of
Bcl-2 will favor apoptosis and thus reduce the rate of
survival [28]. Keeping these in mind, the present study was
designed to study the expression pattern of Bax, and Bcl-2
following the treatments given to U87 cell lines. Current
findings of our experiments demonstrated that NA-2 up-
regulated Bax and down regulated Bcl-2 expression at tran-
scriptional level. Whereas TMZ has shown to increase Bax
expression only and has shown no significant effect on Bcl-2
expression. The effect on the expression of these markers
was more pronounced in cells treated with combination of
NA-2 and TMZ. The up-regulated Bax expression by NA-2
and TMZ and down-regulated Bcl-2 expression by NA-2
only leads to dramatic increase in Bax-Bcl-2 ratio as com-
pared to control and thus apoptosis. Our results are sup-
ported by other studies which shows that NSAIDs like
selective COX-2 inhibitors NS-398 and SC-58125 can down
regulate Bcl-2 and subsequently induce apoptosis in colon
and prostrate cancer cell lines [29]. Whereas celecoxib,
indomethacin and aspirin could induce apoptosis by up-
regulating Bax and activation of caspase-3 [30,31]. Mahd
et al. [32] and Hossain et al. [33] has shown that calcium sa-
licylate and aspirin increase Bax to Bcl-2 ratio in fibrosar-
coma and hepatocellular carcinoma cells by down and up
regulating Bcl-2 and Bax respectively. In case of glioblast-
oma cells 8 mM of asprin reduced Bcl-2 expression to 42%
after 48 hrs whereas only 0.33 mM NA-2 inhibited Bcl-2 ex-
pression to approximately 35% as compare to control which
was increased to 96% when given in combination with
TMZ. Anti-apoptotic Bcl-2 protein has been found to pre-
vent both the loss of the mitochondrial membrane potential
and the efflux of cytochrome c release and inhibit apoptosis.
Bax antagonizes the effect of Bcl-2 that results in release of
cytochrome c in cytosol. Once cytochrome c is released in
the cytosol it contributes to the formation of apoptosome
and subsequent activation of caspases [34].
Caspases, especially caspase-3, are known to act down-
stream of Bax/Bcl-2 control and play a key role in the exe-
cution of apoptosis; responsible for proteolytic cleavage of
Figure 5 Effect of NA-2 and TMZ alone and in combination on active caspase-3 expression. (A) Representative Photomicrographs of
cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in
control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination
treatment group (NA-2 + TMZ). (B) Quantification of cleaved caspase-3 expression using Image J software, cells were counted in the field then
percent intensity (arbitrary unit) was calculated. Each bar represents mean ± S.E.M of three independent experiments. Significant difference
between vehicle control and treated cells was indicated ***P <0.001. The significant difference between the individual drugs NA-2 or TMZ and
their combination treatment is indicated by $$P <0.01, and ###P <0.001 respectively.
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sion of active caspase-3. An enhanced expression of active
caspase-3 was observed after treatment with NA-2 and
TMZ and the effect was further enhanced when cells were
treated in combination. This increased expression of acti-
vated caspase-3 in treated groups as compare to controlsmay be a consequence of increased Bax to Bcl-2 ratio as
explained above and also the highest activated caspase-3
expression was observed in a combination treatment
group where Bax-bcl-2 ratio was highest. Furthermore
several studies have shown NSAIDs like celecoxib, asprin,
indomethacin and nitric oxide giving-NSAID can increase
Hanif et al. Cancer Cell International  (2014) 14:133 Page 8 of 10activation and expression of Caspase-3 [10,35]. Neverthe-
less, further studies are needed to completely understand
the mechanism of action of NA-2 and its synergy with
TMZ.
Conclusion
These results clearly reflect apoptotic activities of NA-2.
It also demonstrates that both these activities of NA-2
can be refined further when given in combination with
TMZ. This may in part be related to the increase in
Bax/Bcl-2 ratio and active Caspase-3 expression.
In future we plan to test the efficacy and mechanism
of action of NA-2 on other cell lines of the similar
tumor types as well as on various other tumor cells to
check if the activity of the NA-2 is tumor specific or it
also inhibit the other tumor types. Further we also want




Test drug N-(2-hydroxyphenyl)acetamide and temozolo-
mide were purchased from Sigma Chemical Company
(St. Louis, MO, USA). Stock concentrations of NA-2
(2000 mM) and TMZ (128 mM) were prepared in sterile
100% DMSO and stored at −20°C. The working solu-
tions of the drugs were prepared fresh from stock solu-
tions by diluting the stock in Dulbecco modified Eagle
medium (DMEM). Six different working concentrations
of NA-2 (0.165 mM, 0.33 mM, 0.66 mM, 1.32 mM,
2 mM) and TMZ (0.025 mM, 0.05 mM, 0.1 mM,
0.2 mM, 0.4 mM, 0.5 mM) were used in the study. In
addition to the above mentioned concentrations, cells
were also treated with various combinations of NA-2
and TMZ (0.33 mM +0.1 mM, 0.33 mM +0.2 mM,
0.66 mM +0.1 mM, 0.66 mM +0.2 mM, 1.32 mM +0.1 mM
and 1.32 mM +0.2 mM) in order to evaluate their com-
bined effect. Cells treated with only DMSO (0.1%) were
used as controls.
Cell cultures
Human glioblastoma cell line U87 (ATCC number:
HTB-14™) was purchased from American Type Tissue
Culture Collection (ATCC, USA) and cultured in DMEM
(Sigma Chemicals) supplemented with 1% penicillin and
streptomycin, 1%, amphotericin B, 1% sodium pyruvate,
1% L-glutamine and 10% fetal bovine serum FBS in a
humidified atmosphere at 37°C containing 5% CO2.
(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyl tetrazolium
bromide (MTT) Assay
The effect of NA-2 and TMZ as a single agent and in
various combinations (mentioned above) on GBM tumor
cell growth was evaluated by the MTT assay [36]. Briefly,monolayer of the cells was trypsinized and re-suspended
in medium containing 10% FBS. The cells (3 × 103 cells/
100 μl) were plated in 96-wells plate and incubated in
humidified atmosphere at 37°C containing 5% CO2 for
24 hrs. Following incubation, media was aspirated and
100 μl of different test concentrations of NA-2 and
TMZ and their various combinations (mentioned above)
in media containing 1% FBS were added. Maximum
DMSO concentration used was less than 0.1%. Cells
treated with 0.1% DMSO in media (1% FBS) were used
as untreated controls. The plates were re-incubated for
24 hrs and after incubation, sample solution in the wells
was flicked off and 100 μl of 0.5 mg/ml MTT dye
(Promega, USA) was added to each well and further
incubated for 3 hrs at 37°C in 5% CO2. After incubation,
supernatant was removed and 100 μl of DMSO (100%)
was added to each well to solubilize formazan. The
absorbance was recorded on 96-wells plate ELISA reader
at 490 nm [37]. The percentage of viable cells following
treatment was normalized to untreated controls. All as-
says were performed in tetraplicates and the percentage
growth inhibition was calculated using the formula [38]:
%cell inhibition ¼ 100‐ At‐Abð Þ= Ac ‐Abð Þf g  100
Where, At, Ab, and Ac stands for absorbance value of
test compound (cells + media + drug), absorbance value
of blank (media + drug), and absorbance value of control
(cells + media + vehicle) respectively.
Synergy analysis of combine drug effects
The coefficient of drug interaction (CDI) was used to
determine the synergistically inhibitory effect of drug
combination, which was calculated as [39]; CDI = AB/
(A × B)
Where, AB, and A or B designate the ratio of the com-
bination groups to control group (DMSO) and the ratio
of single agent (drug) to control group (DMSO) respect-
ively. Thus a CDI value less than, equal to or greater
than 1 specifies that the drugs are synergistic, additive or
antagonistic, respectively [40].
Detection of apoptosis by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay
U87 glioblastoma cells were grown in two chambered
slides (Lab-Tek®) and treated with NA-2 (0.33 mM) and
TMZ (0.1 mM) alone, and in combination (NA-2
0.33 mM + TMZ 0.1 mM) and DMSO for 24 hrs at 37°C
and 5% CO2. After incubation, DeadEnd™ TUNEL assay
system kit (Promega Corporation, USA) was used to de-
tect apoptosis in cell as per manufacturer protocol. Cells
with dark brown nuclei were considered apoptotic [41].
Quantification of apoptotic cells was done by counting
total cells and apoptotic cells in five blindly selected fields
Hanif et al. Cancer Cell International  (2014) 14:133 Page 9 of 10scoring between 350 and 550 cells, and the number of
apoptotic cells was expressed as percentages of the total
cell population [42]. Data from three different experi-
ments were combined and expressed as means ± SEM.
Semi-quantitative RT-PCR
Cells (1×106) were treated for 24 hrs with drugs alone
and their effective combination. Cells treated with
DMSO only served as untreated control. After 24 hours
media was aspirated, cells were trypsinized and centri-
fuged to get the cell pellets. The RNA was then isolated
using SV Total RNA Isolation System (Promega, USA)
kit according to the manufacturer׳' protocol. The con-
centration and purity of isolated RNA was assessed
using spectrophotometer (UV-Spec-1700, Shimadzu).
The isolated RNA samples (500 ng) were reverse-
transcribed into cDNA using RevertAid™ First Strand
cDNA Synthesis Kit (Fermentas, Maryland, USA). Nega-
tive control was also run including RT reaction mixture
omitting reverse transcriptase. The transcribed cDNA (1 μl)
was then amplified using PCR Master Mix (Fermentas,
USA) and oligonucleotide primers corresponding to tran-
scripts of the respective genes. The PCR reaction products
were electrophoretically resolved on ethidium bromide
stained 1% agarose gel and densitometric analysis was
performed using Quantichrome software. Density of each
mRNA band was normalized to its respective house-
keeping gene i.e. β-actin. The primer sequences used in
this study were Bax (sense, 5’-AAGAAGCTGAGCGA
GTGTC-3’) (antisense, 5’-GGCCCCAGTTGAAGTTG
C-3’), Bcl-2 (sense, 5’-ACTTCGCCGAGATGTCCAG
C-3’) (antisense, 5’-GGCAGGCATGTTGACTTCAC-3’),
Caspase-3 (sense, 5’-TTCAGAGGGGATCGTTGTAGAA
GTC-3’) (antisense, 5’- CAAGCTTGTCGGCATACTGT
TTCAG-3’), β-Actin (sense, 5’-GTCCTGTGGCATCCAC
GAAAC-3’) (antisense, 5’ -GCTCCAACCGACTGCTGT
CA-3’) [43-45].
Immunocytochemical analysis
For imunocytochemistry, cells were plated in two cham-
bered slides (Lab-Tek®) and incubated with NA-2
(0.33 mM), TMZ (0.1 mM) alone, their combination (NA-2
0.33 mM + TMZ 0.1 mM) and DMSO (untreated control)
at 37°C and 5% CO2. After 24 hrs cells were fixed with 4%
paraformaldehyde, washed five times with PBS, blocked
with blocking solution (2% bovine serum albumin
(BSA),2% normal goat serum and 0.2%Tween20 all pre-
pared in PBS) at 37°C for 1 hr. Next, cells were washed
with PBS five times and incubated with rabbit anti-cleaved
caspase-3 (Santa Cruz Biotechnology) in 1:100 dilutions at
4°C overnight. On subsequent day cells were washed with
PBS three times and then incubate for 1 hr at room
temperature with secondary antibody Alexa Flour®546 anti-
rabbit IgG at 1:200 dilution in PBS. Then cells were washedagain and counterstained with 4, 6-diamidino-2-phenylin-
dole (DAPI) in 1:500 dilutions in PBS). The stained slides
were then mounted with PBS/glycerol (1:1) and viewed
under a fluorescent microscope (NIKON).
For quantification studies, the images were analyzed
using ImageJ software (National Institutes of Health, USA)
[46]. Briefly, 5 fields were selected blind based and the
intensity of fluorescence was quantified in cells and subse-
quently the background intensity was subtracted from it,
the remaining particles were considered to represent
cleaved caspase-3. Cells were counted and percentage in-
tensity of expression was calculated and means percentage
intensity was found out. Data from three different experi-
ments were combined and expressed as means ± SEM.Statistical analysis
The results obtained from various experiments were ana-
lyzed with SPSS-19 software. Data were expressed as
mean ± standard error of the mean (SEM) of separate ex-
periments (n ≥3) and compared by one-way analysis of
variance (ANOVA) followed by Bonferoni post hoc test.
P <0.05 was considered to be statistically significant.Additional file
Additional file 1: Figure S1. Effect of NA-2 on PSN-1 cells growth
inhibition. Cells were treated with different concentrations of NA-2 for
24 hrs and cell titer blue (CTB) assay was performed. All measurements
were performed in triplicate. NA-2 inhibited the growth of PSN-1 cells in
concentration dependent manner. A significant concentration-dependent
inhibition on the viability of PSN-1 cells was observed. Each bar
represents mean ± S.E.M of three independent experiments.Abbreviations
GBM: Glioblastoma multiforme; TMZ: Temozolomide; MGMT: O6 methyl
guanine– DNA methyl transferase; NSAIDs: Non-steroidal anti-inflammatory
drugs; NA-2: N-(2-hydroxyphenyl) acetamide; MTT: (4, 5-dimethyl
thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide; TUNEL: Terminal
deoxynucleotidyl transferase dUTP nick end labeling; CDI: Coefficient of drug
interaction; Bcl-2: B-cell lymphoma 2; Bax: B-cell lymphoma associated X.
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